Guerbet

1st quarter 2020 revenue

1^st quarter 2020 revenue

 

 

• Revenue growth over 1^st quarter 2020
  • • +1.0% at current exchange rates at €199.2m
    • +1.4% at constant exchange rates at €199.9 million
• Activity affected by the COVID-19 crisis in the 2^nd quarter

 

Villepinte, April 23, 2020 – Guerbet (FR0000032526), a global leader in medical imaging, is reporting its revenue for the first quarter of its 2020 financial year. Revenue totaled €199.2 million at March 31, up 1.0%, including a favorable forex impact of €0.7 million. At constant exchange rates¹, revenue totaled €199.9 million, up 1.4%.

Consolidated Group revenue

In millions of euros, at March 31, 2020	Change (%)	Q1 2020 at current exchange rates	Change (%)	Q1 2020 at constant exchange rates	Reported Q1 2019
Sales in Europe	-14.3%	79.7	-14.4%	79.6	93.0
Sales in Other Markets	+14.6%	119.5	+15.3%	120.3	104.3
Total	+1.0%	199.2	+1.4%	199.9	197.3

Sales driven by Asia and the Americas

In Europe, revenue was down 14.3% at €79.7 million (-14.4% at constant exchange rates). This decline stemmed from a 2019 base effect as well as lower prices in response to the generic of Dotarem.

Revenue in the Americas reached €70.6 million, up 4.6% (+6.4% at constant exchange rates) thanks to greater volumes and despite limited price erosion.

In Asia, volumes are rising sharply in almost all of the region's countries. Revenue totaled €42.1 million, up 34% (+36.7% at constant exchange rates).

Analysis of sales by activity

Diagnostic Imaging sales increased 0.2% (+0.8% at constant exchange rates) and reached €172.2 million compared with €171.9 million in the same period in 2019.

- MRI² sales amounted to €64.4 million, down 3% (-3.2% at constant exchange rates) compared with €66.4 million in the same period in 2019. The main reason is a price effect with the arrival of the generic of Dotarem in most countries of the Europe zone despite an increase in volumes.